

Contemporary outcomes of continuous-flow left ventricular assist devices – a systematic review

Nicholas McNamara^{1,2,3}, Harry Narroway⁴, Michael Williams^{1,2}, John Brookes¹, James Farag^{1,3}, David Cistulli¹, Paul Bannon^{1,3}, Silvana Marasco^{5,6}, Evgenij Potapov^{7,8}, Antonio Loforte⁹

¹Cardiothoracic Surgical Department, Royal Prince Alfred Hospital, Sydney, Australia; ²Faculty of Health and Medicine, University of Sydney, Sydney, Australia; ³Baird Institute of Applied Heart and Lung Research, Sydney, Australia; ⁴Department of Vascular Surgery, Gosford Hospital, Gosford, Australia; ⁵Cardiothoracic Surgical Department, The Alfred, Melbourne, Australia; ⁶Department of Medicine and Surgery, Monash University, Melbourne, Australia; ⁷Deutsches Zentrum für Herz Kreislauf Forschung (DZHK) - Standort Berlin/Charité, Berlin, Germany; ⁸Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin (DHZB), Berlin, Germany; ⁹Division of Cardiac Surgery, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy

Correspondence to: Nicholas McNamara. Cardiothoracic Surgical Department, Royal Prince Alfred Hospital, Sydney, Australia.

Email: nmcn8038@uni.sydney.edu.au.

Background: End stage heart failure is a major cause of morbidity and mortality, and its prevalence is expected to rise with the ageing population. For suitable patients, orthotopic heart transplantation remains the gold standard therapy, however, a paucity of donor organs has led to the development of left ventricular assist devices (LVAD). These devices can be utilized as either a bridge-to-transplant (BTT) or as an alternative to heart transplantation. While these devices can prolong life and improve quality of life, they are associated with a significant number of adverse events. We aim to systematically review the literature to quantify survival and the incidence of adverse events following implantation of continuous-flow LVADs (cf-LVAD).

Methods: A systematic review was performed to determine outcomes following implantation of a cf-LVAD. Primary outcomes were survival and frequency of adverse events (such as bleeding, infection, thrombosis, stroke and right ventricular failure). Secondary outcomes included quality of life and assessment of functional status.

Results: Sixty-three studies reported clinical outcomes of 9,280 patients. Survival after cf-LVAD varied between studies. Industry-funded trials generally reported better overall survival than the single- and multi-center case series, which showed significant variation. The largest registry report documented twelve, twenty-four and forty-eight-month survival rates of 82%, 72% and 57% respectively. The most commonly reported adverse events were gastrointestinal bleeding (GIB), device-related infection, neurological events and right heart failure (RHF). Bleeding, RHF and infection were the most frequent complications experienced by those supported with cf-LVAD, occurring in up to 35%, 40% and 55% of patients, respectively. Quality of life as measured using the Kansas City Cardiomyopathy Questionnaire (KCCQ) and functional status as measured with the 6-minute walk test (6MWT) improved after cf-LVAD implantation with no decline evident two years after implantation.

Conclusions: The paucity of donor hearts has led to the development of left-ventricular assist devices as a BTT or as a destination therapy (DT). Outcomes after cf-LVAD implantation are excellent, with short-term survival comparable to heart transplantation, but long-term survival remains limited due to the incidence of post-implantation adverse events. Despite these complications, quality of life and functional status improve significantly post-implantation and remain improved over the long-term. This study demonstrates the potential benefits of cf-LVAD therapy whilst also identifying adverse events as an area of increased morbidity and mortality.

Keywords: Left ventricular assist device (LVAD); heart failure; systematic review; survival; adverse events



Submitted Feb 01, 2021. Accepted for publication Mar 11, 2021.

doi: 10.21037/acs-2021-cfmcs-35

View this article at: <http://dx.doi.org/10.21037/acs-2021-cfmcs-35>

Introduction

The global prevalence of heart failure is estimated at 65 million cases and is expected to rise as the world population ages (1). End-stage heart failure (ESHF) is a major cause of morbidity and mortality and also contributes significantly to health care costs. Despite the introduction of highly effective medical therapies to reduce mortality and improve function, there remains a significant proportion of patients whose heart failure progresses despite optimal medical therapy. For suitable candidates with advanced and refractory heart failure, orthotopic heart transplant (OHT) remains the definitive therapy and can significantly extend survival and improve function and quality of life (2). However, due to a paucity of donor hearts, left ventricular assist devices (LVADs) have become a viable alternative. The first generation of these devices were volume displacement pumps that generated pulsatile flow (pf-LVADs) analogous to endogenous cardiac contraction. Such devices were utilized as a bridge-to-transplant (BTT) but prolonged use was limited by poor mechanical durability and an unfavourable adverse event profile. The landmark REMATCH trial (3) established the superiority of the Heartmate XVE (Thoratec, Pleasanton, Calif.) over optimal medical therapy for patients with ESHF ineligible for OHT. This marked the beginning of LVAD use as destination therapy (DT). Second- and third-generation continuous-flow (cf)-LVADs were designed to overcome the limitations of the first-generation devices. These devices utilize axial and centrifugal impellers, their smaller size permits implantation in adults and children with smaller body sizes, and their enhanced durability and reliability reduce device malfunction. Despite achieving improved survival and freedom from reoperation for device malfunction compared to pf-LVAD (4-6), cf-LVADs have their own challenges, primarily hemolysis, pump thrombosis, infection and gastrointestinal bleeding (GIB). The present systematic review aimed to examine the short and long-term clinical outcomes of cf-LVADs used as both BTT and DT.

Methods

Search strategy and study selection

Electronic searches were performed using Medline, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and the Database of Abstracts and Reviews of Effects for English-language studies on human subjects published between January 1, 2007 and December 5, 2020. The year 2007 was chosen as this is when contemporary data on CF-LVAD started to become available. Our methods adhered to the guidelines set forth in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement (7). The search algorithm included a combination of Medical Subject Headings (MeSH) and keyword terms related to heart failure, left ventricular assist devices (LVADs) and outcomes of interest (such as survival and adverse effects) (*Figure 1*). Studies including both BTT and DT were included. The reference lists of selected studies were manually reviewed to identify any relevant studies that were potentially missed in the database search. Three reviewers (NM, MW, DC) independently screened the title and abstract of all records identified in the search. When the title and abstract provided insufficient detail to determine study relevance, a full-text copy of the article was reviewed. Before final inclusion, full-text copies of all selected articles were examined for eligibility.

Inclusion and exclusion criteria

Eligible studies were those reporting either survival or adverse event outcome data for patients who had undergone insertion of a cf-LVAD for heart failure. Where multiple studies reported on the same outcome for the same or overlapping patient cohorts, only the most comprehensive or most recent publication was included. The following exclusion criteria were applied: reviews or editorials, conference proceedings, studies with non-human participants, surgical techniques, pediatric studies, studies




Figure 1 PRISMA diagram. LVAD, left ventricular assist device; OHT, orthotopic heart transplant.

that did not separate data for pulsatile and continuous flow devices, studies reporting on mechanical assist devices other than isolated implantable left ventricular assist devices, studies reporting on risk modeling, studies examining post-transplant outcomes in patients bridged with an LVAD, studies that were updated by newer publications and sub-analyses of previously reported results.

Study endpoints

Primary outcomes were survival and frequency of adverse events (such as bleeding, infection, thrombosis, stroke and right ventricular failure). Secondary outcomes included quality of life and assessment of functional status.

Data extraction and quality assessment

Two independent reviewers (NM and MW) extracted data directly from publication texts, tables and figures. The following information was extracted from each study: number of patients implanted with cf-LVAD, device model, duration of follow-up or mean duration of support

or defined time at risk (cumulative patient-years), patient demographics and outcome measures (survival, adverse events, OHT, functional status, quality of life measure). A third reviewer (JB) independently reviewed and confirmed all abstracted data. Disagreements were resolved by consensus. Due to the manner in which outcome data was extracted, each study was effectively treated as a case series regardless of the initial study design, and therefore an assessment of the quality of each study was not performed.

Data synthesis

Data were summarized in tabular form. Where data were reported separately for subgroups, a weighted estimate of the cumulative outcome value was calculated. When relevant data were only presented in graphic form, quantitative estimates were extracted and reported. Narrative synthesis of data was added to supplement the tables, describe data quality and provide a summary. Due to the high likelihood of patient data from single- and multi-center case series being duplicated in registry and trial publications, the authors chose to stratify studies by these

three study types. Due to the significant heterogeneity between studies, pooling of data for meta-analysis was not deemed appropriate.

Role of the funding source

No funding sources were involved in the study design, data collection, data analysis, data interpretation or writing of the report. The corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Results

A total of 627 publications were identified through electronic database searches and from other sources including reference lists (*Figure 1*). After exclusion of duplicate and irrelevant publications, a total of 63 relevant articles were included in the present review (*Table 1*). The majority of studies were observational, single- or multi-center case series. There were 14 industry-funded trials with 4,152 patients, and 46 single- and multi-center case series which included 5,128 patients; 41 of these were retrospective observational studies and five were prospective. Due to significant overlap between registry studies, industry-funded trials and case-series the authors decided to separate studies into these three categories for review.

Prospective registries tended to be used for numerous publications on individual outcomes or specific subgroup analyses, and therefore, there was significant overlap between the registry studies. For this reason, three registry reports were included for comparison: Goldstein *et al.* 2019 (68) was chosen for survival outcomes as it utilized the largest registry and includes most patients from the remaining registry studies. John *et al.* 2011 (67) was selected as a comparison for adverse event and functional outcomes as it was the largest study reporting these outcomes, although it was limited to the HeartMate II device utilized as BTT. Kormos *et al.* 2019 (69) was included for quality-of-life outcomes as these were not reported by the other two registry studies.

Study characteristics

Patient age was similar in the industry-funded studies (weighted mean patient age 57 years, range 49 to 66 years), single- and multi-center case series (53 years, range 35 to 69 years) and the largest registry report (56±12 years).

Comparing studies based on indication for LVAD implantation, patients were youngest in the studies examining BTT and oldest in those examining DT, an expected finding as many DT patients are not considered for OHT based on their age (*Table 2*). The majority of LVAD recipients were male: 80% in industry-funded trials, 79% in case series and 79% in the registry report, and this did not change with indication for LVAD implantation.

There was significant heterogeneity between studies in regard to the number of participants, device implanted, indication for support, proportion of patients with ischemic cardiomyopathy (ICM), Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) profile and duration of follow up (*Table 1*). Cohorts ranged from eight to 1,028 participants, with 30 studies reporting outcomes for less than 100 participants. The proportion of participants with ICM ranged from 6% to 80%. The HeartMate II (Thoratec, Pleasanton, Calif.) and HeartWare HVAD (HeartWare Inc., Framingham, MA) were the most frequently investigated devices. The majority of the industry-funded studies examined a single device, whereas the single- and multi-center case series tended to pool outcomes for all devices implanted at their institution(s). Follow up was largely reported as mean and standard deviation with a few studies reporting median and interquartile range or mean/median duration of support or cumulative time on support (patient-years). A summary of the proportion of patients in each study who experienced an adverse event is presented in *Table 3*. The significant heterogeneity of duration of follow up and reporting made a comparison of the incidence of adverse events difficult, therefore we chose to also present the adverse event rate expressed as events per patient-year (*Table 4*).

Outcome analysis

Survival

Thirteen industry-funded trials and 34 single- and multi-center case series reported survival following cf-LVAD implantation (*Table 5*). Although survival is an objective measure, significant differences in the duration of follow up, censoring of patients at time of transplant and patient loss to follow up made this outcome difficult to report. Actuarial survival was the single measure of survival with the most uniform definition across the studies and was chosen as the outcome measure for comparison. Most studies reported estimated actuarial survival in the range of one to twelve months, with few studies reporting survival

Table 1 Study and patient characteristics													
First author	Year	Study period	Country	Device	Study design	No. of patients	Patient age, years (mean)	Male	ICM	Indication for LVAD [†]	Duration of support	Intermacs class	
Industry-funded trials and associated registries													
Esmore (8)	2007	September 2004–July 2006	Australia, NZ, UK, Norway	VentrAssist	Prospective, observational	30	51	80%	37%	BTT: 100%	Mean follow up 154 days	NR	
Esmore (9)	2008	June 2003–August 2006	Australia	VentrAssist	Prospective, observational	9	65.7	89%	56%	BTT: 56%; DT: 44%	NR	NR	
Morshuis (10)	2010	January 2004–May 2009	Europe	DuraHeart	Prospective, observational	82	57	91%	52%	BTT: 100%	Median duration support 261 days; cumulative duration of support 78 patient-years	NR	
Bogaev (11)	2011	March 2005–April 2008	USA	HM II	Retrospective, observational	465	51.8	78%	45%	BTT: 100%	Mean duration support 339 days	NR	
Strueber (12)	2011	March 2006–December 2008	International	HeartWare HVAD	Prospective, observational	50	48.5	86%	40%	BTT: 100%	Median duration of support 348 days; cumulative duration of support 47.8 patient-years	1: 0%; 2: 22%; 3: 70%; 4–7: 8%	
Park (13)	2012	March 2005–March 2009	USA	HM II	Retrospective, observational	414	63	79%	61%	DT: 100%	Cumulative duration of support 709 patient-years	NR	
Slaughter (14)	2013	August 2008–December 2011	USA	HeartWare HVAD	Prospective, observational	332	52.8	77%	37%	BTT: 100%	NR	1: 5.4%; 2: 34.6%; 3: 42.2%; 17.8%	
Najjar (15)	2014	August 2008–February 2010	USA	HeartWare HVAD	Retrospective, observational	382	53	70%	38%	BTT: 100%	Cumulative duration of support 406.6 patient-years	1: 6%; 2: 35%; 3: 40%; 4–7: 19%	
Maltais (16)	2017	September 2014–November 2015	USA	HM II	Prospective, observational	300	57	83%	46%	BTT: 22%; DT: 78%	Mean followup 6 months	1: 13%; 2: 30%; 3: 40%; 4–7: 17%	
Netuka (17)	2017	January 2011–	Europe	HM II	Prospective, observational	101	56	93%	50%	BTT: 82%; DT: 18%	Cumulative duration of support 205.9 patient-years	1: 14.9%; 2: 22.8%; 3: 32.7%; 4–7: 29.7%	
Rogers (18)	2017	August 2010–May 2012	USA	HM II [148], HeartWare HVAD [297]	Prospective, observational	446	64.6	78%	59%	DT: 100%	Cumulative duration of support 613.96 patient-years	1: 3.4%; 29.6%; 3: 40.4%; 4–7: 26.5%	
Gustafsson (19)	2018	January 2015–	International	HM3	Retrospective, observational	463	55.6	89%	48%	BTT: 66%; DT: 26%; other: 8%	NR	1: 9.3%; 2: 22%; 3: 38%; 4–7: 29.2%	
Schmitto (6)	2019	June 2014–November 2014	International	HM3	Prospective, observational	50	59	90%	NR	BTT: 54%; DT: 46%	Mean follow up 2 years; cumulative duration of support 77.4 patient-years	1: 0%; 2: 10%; 3: 42%; 4–7: 48%	
Mehra (20)	2019	September 2014–August 2016	USA	HM II, HM3	Prospective, observational	1,028	59.4	81%	44%	BTT: 23%; DT: 61%; Other: 16%	Mean follow up 2 years	1: 2.8%; 2: 29.4%; 3: 50.9%; 4–7: 16.9%	
Single- and multi-center case series													
Strüber (21)	2008	March 2004–January 2007	Europe	HM II	Retrospective, observational	101	48.0		60%	BTT: 69%; DT: 31%	Mean duration of support 166 days; cumulative duration of support 45 patient-years	NR	
Loforte (22)	2009	March 2002–December 2008	Italy	HM II	Retrospective, observational	18	52.0	83.3%	72.2%	BTT: 100%	Mean duration of support 217 days	NR	
Sandner (23)	2009	November 1998–July 2007	Austria	MicroMed, HeartWare HVAD, DuraHeart	Retrospective, observational	86	NR	85%	43%	BTT: 100%	Mean duration of support 150 days; cumulative duration of support 35.2 patient-years	NR	
Wieselthaler (24)	2010	March 2006 to November 2008	Vienna, Germany, England, Australia	HeartWare HVAD	Prospective, observational	23	48.0	87%	30%	BTT: 100%	Mean follow up 265 days; mean duration of support 305 days; cumulative duration of support 19 patient-years	NR	
Drews (25)	2011	NR	Germany	All	Retrospective, observational	111	53.6	89%	48%	NR (BTT and DT)	Mean duration of support 703 days	NR	
Aggarwal (26)	2012	January 2005–August 2011	USA	HM II	Retrospective, observational	101	62.0	80%	NR	BTT: 7%; DT: 93%	NR	NR	
Brenyo (27)	2012	November 2006–December 2010	USA	HM II [58] and Jarvik 2000 [3]	Retrospective, observational	61	55.8	92%	61%	BTT: 72%; DT: 28%	NR	NR	
Table 1 (continued)													

Table 1 (continued)												
First author	Year	Study period	Country	Device	Study design	No. of patients	Patient age, years (mean)	Male	ICM	Indication for LVAD [†]	Duration of support	Intermacs class
Menon (28)	2012	August 2008–February 2011	Germany	HM II	Retrospective, observational	40	58.1	65%	80%	BTT: 63%; DT: 23%; other: 15%	Mean follow up 245 days; cumulative duration of support 29 patient-years	NR
Ozbaran (29)	2012	December 2010–August 2011	Turkey	HeartWare HVAD	Retrospective, observational	10	51.8	90%	30%	BTT: 80%; DT 20%	Mean duration of support 251 days	1: 10%; 2: 70%; 3: 20%; 4–7: 0%
Raasch (30)	2012	Jan 2006–Feb 2011	USA	HM II [47] or Jarvik 2000 [14]	Retrospective, observational	61	56.0	67%	39%	BTT: 44%; DT: 56%	NR	NR
Sorensen (31)	2012	September 2002–September 2010	USA	HM II [30], Jarvik 2000 [35]	Retrospective, observational	65	54.0	75%	49%	BTT: 100%	NR	NR
Yuan (32)	2012	June 2000–March 2012	USA	HM II	Retrospective, observational	87	50.0	74%	27%	BTT: 51%; DT: 30%; Other 19%	Mean duration of support 303 days	NR
Dell'Aquila (33)	2013	July 2009–November 2011	Germany	HeartWare HVAD	Retrospective, observational	50	50.6	78%	24%	BTT: 100%	Mean duration of support 285 days; cumulative duration of support 30 patient-years	1: 22%; 2: 10%; 3: 20%; 4–7: 48%
Forest (34)	2013	June 2006–December 2011	USA	HM II [58], HeartWare HVAD [9] and VentrAssist [4]	Retrospective, observational	71	56.0	77%	31%	BTT: 62%; DT: 38%	Mean duration of support 359 days; cumulative duration of support 68 patient-years	NR
Kutty (35)	2013	May 2005–December 2010	UK	HeartWare HVAD [8], VentrAssist [21]	Retrospective, observational	29	45.0	86%	31%	BTT: 41%; other: 59%	Mean duration of support 327 days	1: 0%; 2: 28%; 3: 59%; 4–7: 14%
Lok (36)	2013	March 2006–December 2011	Netherlands	HM II	Prospective, observational	85	45.0	73%	28%	BTT: 100%	Median suration of support 387 days; cumulative duration of support 109 patient-years	1: 25%; 2: 75%; 3: 0%; 4–7: 0%
Meyer (37)	2013	February 2004–2009	Germany	HM II [74] and HeartWare HVAD [41]	Retrospective, observational	115	50.0	88%	39%	BTT: 92%; DT: 8%	NR	NR
Mulloy (38)	2013	January 2009–September 2010	USA	HM II	Retrospective, observational	50	52.3	76%	32%	NR (BTT and DT)	Mean follow up 273 days	NR
Saeed (39)	2013	February 2005–February 2006	Europe	CorAide LVAS	Prospective, observational	21	63.0	85%	42%	NR (BTT and DT)	Median duration of support 192 days; cumulative duration of support 17 patient-years	1: 0%; 2: 28%; 3: 72%; 4–7: 0%
Sakaguchi (40)	2013	October 2008–October 2011	Japan	DuraHeart	Retrospective, observational	23	35.1	74%	13%	BTT: 100%	Median duration of support 559 days; cumulative duration of support 35 patient-years	1: 17%; 2: 48%; 3: 35%; 4–7: 0%
Özalp (41)	2014	January 2009–September 2013	UK	VentrAssist [6] and HeartWare HVAD [96]	Retrospective, observational	102	47.0	87%	39%	BTT: 100%	Median follow up 628 days; median duration of support 462 days	1: 6%; 2: 36%; 3: 25%; 4–7: 33%
Sabashnikov (42)	2014	July 2007–August 2013	UK	HM II [72] and HeartWare HVAD [67]	Retrospective, observational	139	44.0	83%	11%	BTT: 100%	Mean duration of support 514 days	1: 20%; 2: 40%; 3: 30%; 4–7: 10%
Takeda (43)	2014	March 2004–June 2010	USA	HM II [117], VentrAssist [9], DuraHeart [6], DeBakey [6]	Retrospective, observational	140	54.7	79%	36%	BTT: 82%; DT: 18%	Mean duration of support 438 days	NR
Yoshioka (44)	2014	2005 to 2010	Japan	Jarvik 2000	Retrospective, observational	8	55.0	75%	13%	BTT: 75%; DT: 25%	NR	NR
Ertugay (45)	2015	August 2012–August 2014	Turkey	HM II	Retrospective, observational	28	51.2	97%	36%	BTT: 86%; DT: 14%	Mean duration of support 326 days	1: 0%; 2: 21%; 3: 50%; 4–7: 29%
Hata (46)	2015	January 2009–September 2013	Japan	EVAHEART [14], HM II [14], DuraHeart [4]	Retrospective, observational	32	40.2	88%	13%	BTT: 100%	Median duration of support 563 days; cumulative duration of support 33.9 patient-years	1: 0%; 2: 38%; 3: 62%; 4–7: 0%
Iacovoni (47)	2015	January 2006–May 2012	Italy	INCOR	Retrospective, observational	42	56.0	93%	45%	BTT: 86%; DT: 14%	Mean duration of support 525 days; cumulative duration of support 60 patient-years	1: 41%; 2: 33%; 3: 19%; 4–7: 7%
Kimura (48)	2015	April 2011–August 2013	Japan	DuraHeart [10], EVAHEART [21]	Retrospective, observational	31	39.7	84.0%	6.0%	BTT: 100%	Mean follow up 483 days; cumulative duration of support 41 patient-years	1: 19%; 2: 45%; 3: 32%; 4–7: 3%
Table 1 (continued)												

Table 1 (continued)												
First author	Year	Study period	Country	Device	Study design	No. of patients	Patient age, years (mean)	Male	ICM	Indication for LVAD [†]	Duration of support	Intermacs class
Lushaj (49)	2015	January 2008–June 2014	USA	HM II, HeartWare HVAD	Retrospective, observational	128	57.2	84%	23%	BTT: 66%; DT: 34%	24 months (censored at transplant or death)	1: 28%; 2: 28%; 3: 14%; 4–7: 30%
Ammirati (50)	2016	January 2006–February 2012	Italy	MicroMed DeBakey, Berlin Heart Incor, HM II, HeartWare HVAD	Prospective, observational	49	54.0	90%	39%	BTT: 45%; DT: 25%; other: 30%	NR	NR
Daneshmand (51)	2015	January 2005–December 2012	USA	HM II	Retrospective, observational	146	67.0	74%	62%	DT: 100%	NR	1: 9%; 2: 46%; 3: 27%; 4–7: 18%
John (52)	2016	June 1, 2005–June 30, 2014	USA	HM II	Retrospective, observational	278	57.2	81%	58%	BTT: 79%; DT: 21%	Median suration of support 469 days; cumulative duration of support 479 patient-years	NR
Raichlin (53)	2016	January 2009–September 2014	USA	HM II	Retrospective, observational	165	55.6	81%	51%	BTT: 50%; DT: 50%	Median follow up 315 days	1: 28%; 2: 25%; 3: 24%; 4–7: 22%
Sileshi (54)	2016	January 2013–December 2014	USA	HeartWare HVAD	Retrospective, observational	81	52.0	77%	43%	BTT: 100%	Mean follow up 180 days	NR
Xuereb (55)	2016	March 2006 to May 2015	USA	HMI, HeartWare HVAD	Retrospective, observational	240	54.5	75%	37.90%	BTT: 53%; DT: 47%	NR	NR
Centofanti (56)	2017	November 2010–March 2016	Italy	HeartWare HVAD [31], Jarvik 2000 [21], HM3 [1]	Retrospective, observational	32	69.0	84%	53%	BTT: 34%; DT: 41%; other: 25%	Mean follow up 576 days	1: 0%; 2: 16%; 3: 72%; 4–7: 12%
Hanke (57)	2017	May 2009–December 2015	Germany	HeartWare HVAD	Retrospective, observational	102	NR	78%	26%	NR (BTT and DT)	NR	NR
Steffen (58)	2017	October 2004–June 2013	USA	HM II	Retrospective, observational	285	55.0	81%	NR	BTT: 100%	Mean follow up 533 days; mean duration of support 216 days; cumulative duration of support 315 patient-years	NR
Tozzi (59)	2017	November 2015–June 2016	Switzerland	HM3	Prospective, observational	10	57.3	90%	70%	BTT: 70%; DT 30%	NR	1: 20%; 2: 30%; 3: 30%; 4–7: 20%
Carrozzini (60)	2018	January 2012–December 2016	Italy	Heartware HVAD [31], Jarvik 2000 [21], HM3 [1]	Retrospective, observational	53	52.0	89.0%	45.0%	BTT: 100%	Median duration of support 150 days	1: 42%; 2: 30%; 3: 8%; 4–7: 21%
Tahsili-Fahadan (61)	2018	May 2005–December 2013	USA	HM II [326], HeartWare HVAD [46]	Retrospective, observational	372	NR	80%	58%	BTT: 68%; DT: 32%	Mean follow up 664 days; mean duration of support 623 days	NR
Volkovicher (62)	2018	November 2003–March 2016	USA	HM II [403], HeartWare HVAD [123]	Retrospective, observational	526	54.7	78%	45%	NR (BTT and DT)	Cumulative duration of support 871 patient-years	NR
Yin (63)	2018	2004 to 2017	USA	Unspecified axial and centrifugal	Retrospective, observational	351	59.0	82%	45%	BTT: 51%; DT: 34%; other: 15%	Median follow up 196 days	1: 12%; 2: 15%; 3: 45%; 4–7: 28%
Braun (64)	2019	1993–2013	Europe (Denmark, Finland, Norway, Sweden)	HM II and HeartWare HVAD	Retrospective, observational	244	54.1	83%	39%	BTT: 87%; DT 13%	Mean follow up 195 days	1: 12%; 2: 28%; 3: 43%; 4–7: 17%
Jorde (65)	2019	January 2012–December 2016	USA	HM II	Retrospective, observational	124	54.4	75%	36%	BTT: 28%; DT: 72%	Mean follow up 365 days; cumulative duration of follow up 85.5 patient-years	1: 2%; 2: 11%; 3: 84%; 4–7: 3%
Kyvernitakis (66)	2019	January 2006–July 2016	USA	HM II [170] and HeartWare HVAD [42]	Retrospective, observational	212	60 (median)	80%	58%	BTT: 59%; DT: 41%	Median duration of support 257 days	1: 25%; 2: 49%; 3: 12%; 4–7: 14%
Registry reports												
John (67)	2011	2005–2011	INTERMACS registry	HM II	Registry report	1,982	NR	77%	NR	BTT: 100%	Mean duration of support 378 days	1: 17%; 2: 44%; 3: 20%; 4–7: 19%
Goldstein (68)	2019	Inception–December 2017	International	All approved devices	Registry report	16,286	56	79%	44%	BTT: 29%; DT: 42%; other: 27%	NR	NR
Kormos (69)	2019	April 2008–December 2017	USA	All FDA-approved devices	Registry report	18,539	57.1	79%	81%	BTT: 57%; DT: 43%	Mean duration of support 600 days	1: 14%; 2: 37%; 3: 33%; 4–7: 16%

[†], indication for LVAD Other: bridge-to-recovery, bridge-to-decision. LVAD, left ventricular assist device; BTT, bridge-to-transplant; DT, destination therapy; ICM, ischemic cardiomyopathy.

Table 2 Weighted mean age reported for patients stratified by LVAD indication and study design

Indication for LVAD	Patient age (years)		
	Industry	Case series*	All
BTT	53	49	51
Combined	64	67	64
DT	58	55	56
All patients	57	54	56

* four studies that did not report mean age or reported median age were excluded from this analysis.

outcomes beyond two years. The International Registry for Mechanically Assisted Circulatory Support (IMACS) Third Annual Report published 1-, 6-, 12-, 24-, 36-, and 48-month survival rates of 95%, 87%, 82%, 72%, 62% and 57%, respectively (68). These values represent the most recent and comprehensive analysis of survival in patients supported with cf-LVADs. Industry-funded trials reported survival outcomes on par with those of the IMACS reports, while single- and multi-center case series showed the largest variation in values, with some of the poorest survival outcomes often coming from small trials with a large proportion of patients with DT indication.

Bleeding

Bleeding is a frequently reported adverse event and is often described as early or late to differentiate surgical from non-surgical bleeding. Nine industry-funded trials and 26 single- and multi-center case series reported on the incidence of bleeding post cf-LVAD implantation (*Table 3*). Within the literature, the proportion of patients experiencing bleeding that required surgery, varied from 0% to 45% in case series and industry trials, compared with only 7% in the 1,496 patients who received the HeartMate II as BTT reported by John *et al.* 2011 (67). Reasons for such variance include differences in surgical technique (such as the use of lateral thoracotomy for implantation), postoperative anticoagulant regimens and patient risk factors (such as renal function). Examining the studies that reported bleeding event rates (*Table 4*), the industry-funded trials reported a fairly consistent rate of 0.13 to 0.26 events per patient-year, whereas the single- and multi-center case series reported rates that were generally twice that (range 0.16 to 0.59 events per patient-year).

Continuous flow LVAD support has also been associated

with the development of a bleeding diathesis that manifests as late bleeding, predominantly GIB (70,71). Industry-funded studies reported an incidence of GIB ranging from 6% to 35% which is similar to the 0% to 34% reported in case series. Examining studies that reported this outcome as an event rate, this outcome occurs with a frequency of between 0.0 and 0.71 events per patient-year. Greater variation was seen in the case-series compared with the industry trials.

Neurological events

Neurological events including ischemic stroke, hemorrhagic stroke, and transient ischemic attack (TIA) are relatively common after cf-LVAD implantation and can be a cause of significant morbidity and mortality. Eleven industry-funded trials and 22 single- and multi-center case series reported the incidence of neurological events after LVAD implantation (*Table 3*). The risk of ischemic and hemorrhagic stroke ranged from 0% to 26%, and 0% to 16%, respectively. Follow up in these studies ranged from approximately six months to two years, with a higher risk of stroke generally associated with prolonged duration of device support. This observation is in line with the findings of the fifth INTERMACS annual report, which demonstrated the 6-, 12-, and 24-month risk of stroke to be 7%, 11% and 17%, respectively (72).

Infection

Despite the smaller diameter power cable compared to the first-generation pf-LVAD devices, the cf-LVAD driveline remains a source of entry for bacteria with the potential for developing driveline infection (DLI), pump pocket infection or sepsis. Ten industry-funded trials and twenty single- and multi-center case series (*Table 3*) reported outcomes for device-related infection and sepsis. DLI was one of the most common complications after LVAD implantation, occurring in 5% to 44% of patients. Despite the high rates of DLI, pump pocket infection rates were much lower, ranging from 0% to 22% among the various studies. Reported incidence of sepsis was almost as varied as that of DLI, with rates of sepsis ranging from 0% to 33%. When reported as events per patient-year, DLI (0.13 to 1.27) was more common than sepsis (0.07 to 0.46) and pump pocket infection (0.01 to 0.07).

Pump thrombosis

Six industry-funded trials and eight single- and multi-

Table 3 Incidence of adverse events (%)														
First author	Year	No. of patients	Indication for LVAD	Support duration (patient-years)	Bleeding		Neurological		Device malfunction	Infection			Right heart failure	
					Requiring surgery	GIB	Ischaemic stroke	Haemorrhagic stroke	Thrombosis requiring exchange	DLI	Sepsis	Pocket infection	RVAD	Inotrope
Industry-funded trials and associated registries														
Esmore (9)	2008	9	BTT: 100%	Mean 154 days follow up			11.10%			33.30%	11.10%	22.20%		11.1%
Bogaev (11)	2011	465	BTT: 100%	431.2	21.50%		4.90%	5.10%			21%		6.2%	19.7%
Strueber (12)	2011	50	BTT: 100%	47.8	20%		4%	8%	2%	18%	10%		6%	6.0%
Park (13)	2012	414	DT: 100%	709	22.90%		8.00%	6.80%	2.40%	28.30%	30.40%	7.70%	5.30%	21.50%
Najjar (15)	2014	382	BTT: 100%	406.6	14.90%	15.40%	5.20%	8.30%	4.20%	19.60%	18.80%		3.90%	29.8%
Maltais (16)	2017	300	BTT: 22%; DT: 78%	Mean 180 days follow up	16%	21%	4%	2.70%	4.30%	5%			5%	11.6%
Netuka (17)	2017	101	BTT: 82%; DT 18%	205.96			5%	4%						
Rogers (18)	2017	446	DT: 100%	613.96	13.60%	34.70%	14.40%	11.30%	7.90%	18.20%	20.90%	–	2.90%	31.70%
Gustafsson (19)	2018	463	BTT: 66%; DT: 26%; other: 8%	NR	10%	6%	3.90%	1.50%		11.70%	9.10%		6.70%	8.0%
Schmitto (6)	2019	50	BTT: 54%; DT: 46%	77.4	16%	20%	16%	8%	–	24%	22%		4%	14.0%
Mehra (20)	2019	1,020	BTT: 23%; DT: 61%; other: 16%	Mean follow up 2 years	13.60%	27.60%	9.20%	6.70%	5.90%	21.40%	15%		4.10%	27.1%
Single- and multi-center case series														
Strüber (21)	2008	101	BTT: 69%; DT: 31%	44.6	–	–	–	–	–	20.80%	–	3%	–	–
Loforte (22)	2009	18	BTT: 100%	Mean 217 days support	33.30%	–	–	5.60%	–	11.10%	–	–	11.10%	–
Sandner (23)	2009	86	BTT: 100%	35.2	25.60%	–	10.50%	11.60%	–	–	–	–	5.80%	–
Wieselthaler (24)	2010	23	BTT: 100%	19	21.7%	13%	4.30%	4.30%	6.70%	34.80%	13%	–	4.30%	–
Aggarwal (26)	2012	101	BTT: 7%; DT: 93%	NR	–	22.8	–	–	–	–	–	–	–	–
Brenyo (27)	2012	61	BTT: 72%; DT: 28%	NR	–	–	11%	–	–	–	–	–	–	–
Menon (28)	2012	40	BTT: 63%; DT: 23%; other: 15%	29	15%	7.50%	5%	–	–	–	–	–	–	–
Ozbaran (29)	2012	10	BTT: 80%; DT 20%	Mean 251 days support	30%	–	–	1%	–	–	–	–	–	–
Sorensen (31)	2012	65	BTT: 100%	NR	23.10%	–	–	–	–	–	–	–	10.70%	–
Yuan (32)	2012	133	BTT: 51%; DT: 30%; other 19%	Mean 303 days support	–	–	–	–	–	–	–	–	21.50%	–
Dell'Aquila (33)	2013	50	BTT: 100%	30.3	36%	26%	26%	4%	–	14%	28%	–	–	–
Kutty (35)	2013	29	BTT: 41%; other: 59%	Mean 327 days support	–	–	–	–	–	–	–	–	13.80%	–
Lok (36)	2013	85	BTT: 100%	109.1	–	5%	11%	5%	–	14%	27%	5%	4.70%	27.10%
Meyer (37)	2013	115	BTT: 92%; DT: 8%	NR	45.20%	–	–	–	4.30%	27.80%	–	0.9%%	–	–
Mulloy (38)	2013	50	NR (BTT and DT)	Mean 273 days follow up	22%	22%	8%	–	–	–	14%	2%	–	–
Saeed (39)	2013	21	NR (BTT and DT)	17	–	–	–	–	–	–	–	–	–	–
Sakaguchi (40)	2013	23	BTT: 100%	35	13%	–	4.30%	13%	–	13%	–	21.70%	21.70%	–
Sabashnikov (42)	2014	139	BTT: 100%	Mean 514 days support	–	–	9%	14%	–	25%	10%	1%	–	–
Takeda (43)	2014	140	BTT: 82%; DT: 18%	Mean 438 days support	–	–	–	–	–	–	–	–	3.60%	–
Table 3 (continued)														

Table 3 (continued)														
First author	Year	No. of patients	Indication for LVAD	Support duration (patient-years)	Bleeding		Neurological		Device malfunction	Infection			Right heart failure	
					Requiring surgery	GIB	Ischaemic stroke	Haemorrhagic stroke	Thrombosis requiring exchange	DLI	Sepsis	Pocket infection	RVAD	Inotrope
Yoshioka (44)	2014	8	BTT: 75%; DT: 25%	NR	0%	–	12.50%	–	–	–	–	–	–	–
Ertugay (45)	2015	28	BTT: 86%; DT: 14%	Mean 326 days support	10%	–	3%	10%	7%	7%	7%	10%	–	7%
Iacovoni (47)	2015	42	BTT: 86%; DT: 14%	60	–	0%	–	–	0%	–	–	–	–	–
Kimura (48)	2015	31	BTT: 100%	41	–	0%	–	–	–	–	26%	–	–	–
Lushaj (49)	2015	128	BTT: 66%; DT: 34%	30 day outcomes	6.25%	–	–	–	–	–	–	–	–	2.30%
Daneshmand (51)	2015	146	DT: 100%	NR	–	–	6.90%	4.80%	–	–	–	–	–	–
Raichlin (53)	2016	165	BTT: 50%; DT: 50%	Median 315 days follow up	–	18%	–	–	–	8%	–	–	–	–
Sileshi (54)	2016	81	BTT: 100%	Mean 180 days follow up	–	7%	7%	1%	–	8%	–	–	4%	–
Xuereb (55)	2016	240	BTT: 53%; DT: 47%	NR	13.80%	29.60%	6.70%	8.30%	–	10%	–	1.70%	22.10%	–
Centofanti (56)	2017	32	BTT: 34%; DT: 41%; other: 25%	Mean 576 days follow up	–	–	–	–	0%	–	–	–	–	–
Hanke (57)	2017	102	NR (BTT and DT)	NR	–	–	8.80%	–	–	–	–	–	–	–
Tozzi (59)	2017	10	BTT: 70%; DT 30%	NR	40%	–	0%	0%	0%	20%	–	–	40%	–
Carrozzini (60)	2018	53	BTT: 100%	Median 150 days support	18.90%	20%	2%	4%	11%	21%	4%	–	17%	19%
Tahsili-Fahadan (61)	2018	372	BTT: 68%; DT: 32%	Mean 664 days follow up	–	–	9.40%	7%	–	–	–	–	–	–
Volkovicher (62)	2018	526	NR (BTT and DT)	871.4	–	26.80%	15.60%	16.20%	–	10.50%	33.30%	6.10%	–	–
Yin (63)	2018	351	BTT: 51%; DT: 34%; other: 15%	Median 196 days follow up	–	34.20%	–	–	–	–	–	–	–	–
Braun (64)	2019	244	BTT: 87%; DT 13%	Mean 195 days follow up	–	12.30%	–	–	7.60%	44.40%	22.50%	–	–	24.40%
Jorde (65)	2019	124	BTT: 28%; DT: 72%	85.5	–	28.20%	5.60%	5.60%	–	8.90%	–	–	–	–
Kyvernitakis (66)	2019	212	BTT: 59%; DT: 41%	Median 257 days support	–	–	–	–	–	31%	31%	–	–	–
BTT, bridge to transplant; DT, destination therapy; DLI, driveline infection; GIB, gastrointestinal bleeding; LVAD, left ventricular assist device; RVAD, right ventricular assist device.														

Table 4 Incidence of adverse events expressed as number of events per patient-year														
First author	Year	No. of patients	Indication for LVAD	Support duration (patient-years)	Bleeding		Neurological		Device malfunction	Infection			Right heart failure	
					Requiring surgery	GIB	Ischaemic stroke	Haemorrhagic stroke	Thrombosis requiring exchange	DLI	Sepsis	Pocket infection	RVAD	Inotrope
Industry-funded trials and associated registries														
Bogaev (11)	2011	465	BTT: 100%	431.2	0.26	–	0.05	0.05	–	–	0.31	–	–	–
Strueber (12)	2011	50	BTT: 100%	47.8	0.23	–	0.04	0.08	0.02	0.20	0.10	–	0.06	0.06
Park (13)	2012	414	DT: 100%	709	0.17	–	0.05	0.04	0.01	0.27	0.30	0.06	0.03	0.14
Najjar (15)	2014	382	BTT: 100%	406.6	0.16	0.27	0.06	0.08	0.04	0.25	0.23	–	0.04	0.32
Netuka (17)	2017	101	BTT: 82%; DT 18%	205.96	–	–	0.02	0.02	–	–	–	–	–	–
Rogers (18)	2017	446	DT: 100%	613.96	0.13	0.52	0.13	0.09	–	1.27	0.18	–	0.02	0.27
Schmitto (6)	2019	50	BTT: 54%; DT: 46%	77.4	0.14	0.18	0.10	0.05	0.00	0.22	0.14	–	0.03	0.09
Single- and multi-center case series														
Strüber (21)	2008	101	BTT: 69%; DT: 31%	44.59	–	–	0.07	0.05	–	0.37	–	–	–	–
Wieselthaler (24)	2010	23	BTT: 100%	19	0.16	0.16	0.05	0.05	–	0.42	0.16	–	0.05	–
Menon (28)	2012	40	BTT: 63%; DT: 23%; other: 15%	28.95	0.24	0.10	0.07	–	–	–	–	–	–	–
Dell'Aquila (33)	2013	50	BTT: 100%	30.3	0.59	0.43	0.43	0.07	–	0.23	0.46	–	–	–
Lok (36)	2013	85	BTT: 100%	109.1	–	0.05	0.08	0.04	–	0.13	0.31	0.04	0.04	0.21
Meyer (37)	2013	115	BTT: 92%; DT: 8%	NR	0.39	–	–	–	0.04	0.24	–	–	–	–
Sabashnikov (42)	2014	139	BTT: 100%	Mean duration of support 514 days	–	–	0.07	0.06	–	0.20	0.08	0.01	–	–
Hata (46)	2015	32	BTT: 100%	33.9	0.32	–	–	–	–	–	–	–	–	–
Iacovoni (47)	2015	42	BTT: 86%; DT: 14%	60	–	0.00	–	–	0.00	0.33	0.07	–	–	–
John (52)	2016	267	BTT: 79%; DT: 21%	479.01	–	0.14	–	–	–	0.15	–	–	–	–
Volkovicher (62)	2018	526	NR (BTT and DT)	871.4	–	0.25	0.11	0.11	–	0.13	0.41	0.07	–	–
Jorde (65)	2019	124	BTT: 28%; DT: 72%	84.7	–	0.71	0.08	0.08	–	0.18	–	–	–	–
LVAD, left ventricular assist device; BTT, bridge to transplant; DT, destination therapy; GIB, gastrointestinal bleeding; DLI, driveline infection; RVAD, right ventricular assist device.														

Table 5 Actuarial survival											
First author	Year	No. of patients	Indication for LVAD	1 month	6 months	12 months	18 months	24 months	36 months	48 months	5 years
Industry-funded trials and associated registries											
Esmore (8)	2007	9	BTT: 56%; DT: 44%	-	-	-	-	-	-	-	-
Esmore (9)	2008	30	BTT: 100%	78%	-	-	-	-	-	-	-
Morshuis (10)	2010	82	BTT: 100%	-	85%	79%	-	58%	-	-	-
Bogaev (11)	2011	465	BTT: 100%	93.7%	-	84.1%	74.6%	73.0%	-	-	-
Strueber (12)	2011	50	BTT: 100%	-	90%	84%	-	79%	-	-	-
Park (13)	2012	414	DT: 100%	-	-	71.4%	-	61.4%	-	-	-
Najjar (15)	2014	382	BTT: 100%	-	91%	84%	-	-	-	-	-
Maltais (16)	2017	300	BTT: 22%; DT: 78%	-	89%	-	-	-	-	-	-
Netuka (17)	2017	101	BTT: 82%; DT 18%	-	-	-	-	-	-	-	-
Rogers (18)	2017	446	DT: 100%	-	-	-	-	-	56%	-	-
Gustafsson (19)	2018	463	BTT: 66%; DT: 26%; other: 8%	-	92%	-	-	-	-	-	-
Schmitt (6)	2019	50	BTT: 54%; DT: 46%	-	92.0%	81%	-	74%	-	-	-
Mehra (20)	2019	1,028	BTT: 23%; DT: 61%; other: 16%	-	85%	79%	-	68%	-	-	-
Single- and multi-center case series											
Strüber (21)	2008	101	BTT: 69%; DT: 31%	-	67%	-	-	-	-	-	-
Wieselthaler (24)	2010	23	BTT: 100%	-	91%	86%	-	-	-	-	-
Drews (25)	2011	111	NR (BTT and DT)	-	-	82%	-	63%	-	-	-
Aggarwal (26)	2012	101	BTT: 7%; DT: 93%	-	-	48%	-	-	-	-	-
Menon (28)	2012	40	BTT: 63%; DT: 23%; other: 15%	88%	-	-	-	-	-	-	-
Sorensen (31)	2012	65	BTT: 100%	91%	-	-	-	-	-	-	-

Table 5 (continued)

Table 5 (continued)

First author	Year	No. of patients	Indication for LVAD	1 month	6 months	12 months	18 months	24 months	36 months	48 months	5 years
Yuan (32)	2012	87	BTT: 51%; DT: 30%; other 19%	-	-	52%	-	-	-	-	-
Dell'Aquila (33)	2013	50	BTT: 100%	82%	-	78%	-	76%	-	-	-
Kutty (35)	2013	29	BTT: 41%; other: 59%	97%	-	86%	-	-	-	-	-
Lok (36)	2013	85	BTT: 100%	-	85%	81%	-	76%	76%	68%	-
Meyer (37)	2013	115	BTT: 92%; DT: 8%	86%	-	-	-	69%	-	-	-
Özalp (41)	2014	102	BTT: 100%	-	-	75%	-	66%	-	-	-
Sabashnikov (42)	2014	139	BTT: 100%	89%	-	76%	-	66%	-	-	-
Takeda (43)	2014	140	BTT: 82%; DT: 18%	-	-	83%	-	-	75%	-	61%
Yoshioka (44)	2014	8	BTT: 75%; DT: 25%	-	-	100%	-	86%	-	-	-
Ertugay (45)	2015	28	BTT: 86%; DT: 14%	-	96%	90%	-	-	-	-	-
Hata (46)	2015	32	BTT: 100%	-	-	96%	-	-	72%	-	-
Iacovoni (47)	2015	42	BTT: 86%; DT: 14%	93%	-	74%	-	60%	-	-	-
Kimura (48)	2015	31	BTT: 100%	-	93%	86%	-	86%	-	-	-
Lushaj (49)	2015	128	BTT: 66%; DT: 34%	-	91%	88%	75%	-	64%	-	-
Ammirati (50)	2016	49	BTT: 45%; DT: 25%; other: 30%	-	-	76%	-	71%	-	-	-
Daneshmand (51)	2015	146	DT: 100%	-	-	-	-	89%	-	-	-
John (52)	2016	278	BTT: 79%; DT: 21%	94%	-	77%	-	65%	60%	50%	48%
Sileshi (54)	2016	81	BTT: 100%	91%	79%	-	-	-	-	-	-
Xuereb (55)	2016	240	BTT: 53%; DT: 47%	88%	86%	81%	-	65%	-	-	-

Table 5 (continued)

Table 5 (continued)

First author	Year	No. of patients	Indication for LVAD	1 month	6 months	12 months	18 months	24 months	36 months	48 months	5 years
Centofanti (56)	2017	32	BTT: 34%; DT: 41%; other: 25%	100%	–	76%	–	66%	–	–	–
Hanke (57)	2017	102	NR (BTT and DT)	–	–	82%	–	–	–	–	–
Steffen (58)	2017	285	BTT: 100%	93%	83%	77%	–	–	59%	–	50%
Carrozzini (60)	2018	53	NR	96%	–	89%	–	80%	–	–	–
Tahsili-Fahadan (61)	2018	372	BTT: 68%; DT: 32%	–	–	–	–	68%	–	58%	–
Volkovicher (62)	2018	526	NR (BTT and DT)	90%	80%	74%	–	67%	–	–	–
Yin (63)	2018	351	BTT: 51%; DT: 34%; other: 15%	–	–	81%	–	67%	–	–	–
Braun (64)	2019	244	BTT: 87%; DT: 13%	–	–	75%	–	69%	63%	–	–
Kyvernitakis (66)	2019	212	BTT: 59%; DT: 41%	–	86%	75%	73%	–	–	–	–

LVAD, left ventricular assist device; BTT, bridge to transplant; DT, destination therapy.

center case series (*Table 3*) reported the incidence of pump thrombosis requiring device exchange. Three studies reported no patients requiring device replacement for pump thrombosis, while the remaining eleven studies reported an incidence of between 2% and 11% of LVAD recipients. This is still significantly less than the nearly 50% of patients implanted with the first-generation HeartMate XVE who experienced device exchange due to malfunction or infection at 18 months (73). Expressed as the number of events per patient-year, this was a relatively uncommon occurrence (less than 0.04 events per patient-year).

Right heart failure (RHF)

RHF has been associated with poorer outcomes and increased short-term mortality (74). In this review ten industry-funded studies and sixteen single- and multi-center case series (*Table 3*) reported on the incidence of RHF either requiring prolonged inotropic support or placement of a right ventricular assist device (RVAD). RHF requiring prolonged inotropic support was present in 2% to 32% of patients, while RHF requiring placement of an RVAD was reported in 2.9% to 40% of patients. This is significantly higher than the 19.7% and 6.2% of patients requiring prolonged inotropic support and RVAD implantation reported from the HMII Trial and Continued Access Protocol registry (11). Sensitivity analysis was performed where studies with less than 100 participants were excluded, following which the rates of prolonged inotropic support and requirement for RVAD placement were 8% to 32% and 3% to 7% respectively in the industry-funded trials. Similar sensitivity analysis performed looking at the single- and multi-center case series showed a requirement for prolonged inotropic support and RVAD placement of 2% to 24% and 4% to 22%, respectively. This sensitivity analysis shows that the incidence of RVAD placement was overestimated in several small studies but is generally higher than the rates reported in the large clinical trials, perhaps reflecting the influence of patient selection through the use of inclusion and exclusion criteria.

Health related quality of life (HRQoL)

Commonly used measures of health-related quality of life were the Kansas City Cardiomyopathy Questionnaire (KCCQ), and Minnesota Living with Heart Failure Questionnaire (MLHFQ). Overall, quality of life was infrequently assessed and reported exclusively by industry-funded trials. The KCCQ is a self-administered

questionnaire that examines physical function, social function, symptoms and quality of life. An overall summary score can be derived from the various domains, measured on a scale from 0–100, in which higher scores reflect better health status (75). Five industry-funded trials (11,12-14,20) assessed HRQoL after LVAD implantation using the KCCQ. Baseline scores were similar, ranging from 28 to 40, and significant differences were detected by six months (63 to 72). Two studies continued assessing KCCQ out to 24 months and showed that the improvements achieved at six months were maintained 12- and 24-month post LVAD-implantation (*Table 6*). These findings were consistent with those reported by Kormos and colleagues (69) in a large registry report that included over 18,000 patients who received cf-LVAD for BTT and DT.

The MLHFQ questionnaire assesses two domains, physical and emotional, and provides a summary score on a scale from 0–105 (76). However, unlike the KCCQ, higher scores on the MLHFQ correlate with more significant impairment in health-related quality of life. Two industry-funded trials (11,13) examined quality of life using the MLHFQ and demonstrated significant improvements by six months that were maintained through to 12- and 24-month post LVAD implantation.

Functional outcomes

Commonly used tools for the assessment of function after LVAD implantation were the New York Heart Association (NYHA) status and the 6-minute walk test (6MWT). Four industry-funded trials (6,11,13,20) assessed NYHA status at baseline and post-LVAD implantation. Essentially all patients were classified as NYHA III or IV at baseline, with 79–85% improving to NYHA I-II at six months and no evidence of deterioration in status at 24 months. Three industry-funded trials (11,14,20) assessed 6MWT at baseline and post-LVAD implantation. Many patients were unable to participate in the 6MWT at baseline. Significant improvements in distances walked were evident by six months and maintained through to 24 months post LVAD-implantation.

Discussion

LVAD therapy offers patients with ESHF the potential for improved survival, HRQoL and functional status compared with medical therapy alone. However, there are several risks associated with these devices that can limit survival

Table 6 Functional and quality of life outcomes																			
First author	Year	No. of patients	Indication for LVAD (%)	NYHA status				6 MWT				MLHFQ				KCCQ			
				NYHA I-II baseline	NYHA I-II 6 months	NYHA I-II 12 months	NYHA I-II 24 months	6MWT baseline (m)	6MWT 6 months (m)	6MWT 12 months (m)	6MWT 24 months (m)	MLHFQ baseline (mean)	MLHFQ 6 months (mean)	MLHFQ 12 months (mean)	MLHFQ 12 months (mean)	KCCQ baseline	KCCQ 6 months	KCCQ 12 months	KCCQ 24 months
Industry-funded trials and associated registries																			
Bogaev (11)	2011	465	BTT: 100%	0	85%	–	–	225	333	–	–	72.5	36.1	–	–	29	67	–	–
Strueber (12)	2011	50	BTT: 100%	–	–	–	–	–	–	–	–	–	–	–	–	30	72	–	–
Park (13)	2012	414	DT: 100%	0	81%	77%	80%	–	–	–	–	75	33	32	31	28	68	69	70
Slaughter (14)	2013	332	BTT: 100%	–	–	–	–	75	255	–	–	–	–	–	–	37	68	–	–
Schmitto (6)	2019	50	BTT: 54%; DT: 46%	0	–	–	88%	–	–	–	–	–	–	–	–	–	–	–	–
Mehra (20)	2019	1,028	BTT: 23%; DT: 61%; other: 16%	0	79%	81%	79%	132	318	329	340	–	–	–	–	40	70	68	69
Registry report																			
Kormos (69)	2019	18,539	BTT: 67% DT: 43%	–	–	–	–	–	–	–	–	–	–	–	–	34.5	67	66.8	65.9
NYHA, New York Heart Association; 6 MWT, 6-minute walk test; MLHFQ, Minnesota Living with Heart Failure Questionnaire; KCCQ, Kansas City Cardiomyopathy Questionnaire; LVAD, left ventricular assist device; BTT, bridge to transplant; DT, destination therapy.																			

and long-term use if not appropriately managed. The most commonly reported major events after LVAD implantation are bleeding requiring surgery, GIB, neurological events, pump thrombosis, infection and right ventricular failure. Definitions for these adverse events varied between studies included in this review, but for the majority the INTERMACS definitions were used. Significant variances were seen in the reported incidence of adverse events between studies due mainly to the differing follow-up periods, as many of the reported adverse outcomes are proportional to the time at risk. The significance of these adverse events becomes pronounced when we consider that more patients are receiving LVAD with a DT indication and the cumulative risk of GIB, infection and stroke increases proportionally with the duration of support (77).

Previous reviews have examined associations between LVAD and single adverse events, compared outcomes following LVAD versus OHT, and examined outcomes following OHT in patients bridged with LVAD against those who were not. The last review that attempted to broadly examine outcomes after cf-LVAD was performed by McIlvennan *et al.* (78) in 2014, and there has subsequently been a large volume of relevant publications in the interceding six years. Another considerable change over this time has been the expansion of devices approved for use, both as BTT and DT, a shift towards LVAD as DT (at least in the USA) and the development of new third-generation centrifugal flow devices. For these reasons we believed there was need for an updated systematic review reporting survival and adverse outcomes after cf-LVAD implantation. More specific analysis of individual devices, or even centrifugal- versus axial-flow LVADs is not within the scope of this review and should be the subject of their own, more specific systematic review.

The use of cf-LVAD has been shown to have similar two-year survival to that of OHT (12,79) and offers the potential to improve quality of life and functional status of patients with ESHE. Survival after cf-LVAD implantation in this review was generally good, with the results of industry-funded trials similar to those published by International Society of Heart and Lung Transplantation (ISHLT) in the IMACS third annual report. Single- and multi-center registries published some of the poorer survival outcomes, and generally these results were from small studies with a large proportion of DT recipients. Other possible causes for this observed difference include less selective inclusion criteria, potentially sicker or more comorbid patients, and the fact that some of the small single-centre case series were

publications of a unit's initial experience with a particular device.

Infection has always been an important cause of morbidity and mortality in patients supported with LVAD. In the pivotal REMATCH trial (3) the survival benefit of pf-LVAD failed to extend beyond the first year of support and the predominant cause of death in the treatment arm was sepsis, responsible for 41% of deaths. Since the introduction of cf-LVAD devices, multiple studies have demonstrated a reduction in DLI and sepsis and near eradication of pump pocket infections (80-83). Recognition of this potentially fatal complication has led to the early identification and treatment of DLI and subsequently reduced the morbidity and mortality associated with device related infections.

Bleeding has always been a frequent adverse event following LVAD implantation, but the introduction of cf-LVAD devices has seen a significant change in the type of bleeding experienced by patients. While the pulsatile devices were associated with frequent early postoperative bleeding the newer devices are associated with higher rates of late bleeding, particularly GIB (4,70,83,84-86). The main differences between the two devices are the requirement for the formation of a large pump pocket for the pf-LVAD, and the requirement for anticoagulation with the cf-LVAD to prevent pump thrombosis. While the first difference may explain the reduced rates of early postoperative bleeding, anticoagulation alone does not explain the increased risk of late bleeding. Observed rates of late bleeding in cf-LVAD patients of 63 GIB events/100 patient-years significantly exceeds the documented rates of bleeding in patients receiving anticoagulation for mechanical valves (4.6 bleeding events/100 patient-years) (87,88). Additionally, several studies have observed bleeding in the absence of supratherapeutic INR and no significant difference in the average INR observed at the time of bleeding compared with those without bleeding (70,84,87,89). These two observations and the fact that removal of the device for cardiac recovery or heart transplantation results in an abatement of GIB (84) suggest that there are specific factors associated with cf-LVADs that are responsible for the development of a bleeding diathesis. Several proposed mechanisms centre around the development of an acquired von Willebrand syndrome and the loss of pulsatile flow (71,90-92). An acquired von Willebrand syndrome develops in all patients on cf-LVAD support as demonstrated by the decrease in or absence of high molecular weight (HMW) von Willebrand factor (vWF) multimers (26,71). The cause of this is two-fold: firstly, these HMW multimers

rely upon pulsatile flow for their release from endothelial cells; secondly, the high shear stress created by axial-flow impellers results in the destruction of the largest multimers (26). These HMW vWF multimers are essential for platelet activation and aggregation at sites of bleeding, particularly at sites of high shear stress such as arteriovenous malformations (AVMs) (93-96). The second factor thought to contribute to the bleeding diathesis is the presence of non-pulsatile flow, which may actually increase the development of gastrointestinal angiodysplasia. Investigators have proposed that narrow pulse pressure may increase intraluminal pressure and lead to dilatation of the sub-mucosal venous plexus, predisposing to angiodysplasia, AVM formation and eventually bleeding (86,97,98). There are two observations supporting the idea that the loss of pulsatile flow contributes to the development of GIB: firstly, the observation that the absence of aortic valve opening was associated with over a four-fold increase in the risk of non-surgical bleeding (70), and secondly, that reduction in flow rates to allow aortic valve opening tends to restore pulsatility and ameliorates GIB (87,98).

Newer, third generation LVADs utilise a magnetically levitated centrifugal impeller to generate flow. The small housing and contactless bearing reduce blood-biomaterial interface, reduce heat generation, and permit regular alterations in pump speed to generate a pseudo-pulsatile flow pattern. Early results appear to confirm that these improvements have resulted in a reduced risk of GIB (20,99). However, as third generation devices are relatively new, results are mostly from industry-funded trials and long-term follow-up is lacking in comparison to axial-flow devices.

An observation of this review was that industry-funded trials tended to have less variance in the reported proportions of patients experiencing adverse outcomes compared with those results reported from single- and multi-center case series. This is likely due to a highly selected patient cohort with more stringent inclusion and exclusion criteria, and a more uniform definition of outcomes. Another potential contributing factor may be the presence of small sample size bias in the case series; but without assessing the data statistically for the presence of such bias, we cannot ignore the fact that the difference may also represent true outcomes from a less restrictive cohort. Thus, we must be careful not to apply the findings from industry-funded trials to all patients, particularly those who may be older, carry more comorbidities or are receiving the device for DT indications, without some thought as to the applicability of those results to the individual.

This review observed a trend towards higher rates of adverse events reported in DT trials than BTT trials as has been previously reported (100). It is difficult to know whether this is truly the case as there was a paucity of trials assessing outcomes for DT-only cohorts. Whether this observation represents the outcomes of a generally older and sicker patient cohort or is due to prolonged duration of cf-LVAD support is unclear and beyond the scope of this review but should be kept in mind when interpreting the data presented in the above tables.

Limitations

There are several limitations to this review that need addressing. Firstly, the authors endeavored to produce a comprehensive systematic review of cf-LVAD outcomes. The broad inclusion criteria were designed to capture as many studies reporting survival, adverse events, quality of life and functional status as possible. The downside to such an approach is the inclusion of a large number of studies, with significant overlap and a large degree of heterogeneity between studies in regard to patient inclusion criteria, baseline characteristics and duration of follow up. The lack of standard definitions, non-uniform reporting of outcome event rates and varying durations of follow up limited the ability to pool data and meant that meta-analysis was not appropriate. Secondly, while there were a few randomized trials and prospective cohort studies, the way the data were extracted from the studies meant that each study was essentially treated as a case-series, precluding any assessment of the quality of the evidence as case-series are considered to be of poor quality and there are no validated tools for this study design. Additionally, the mixing of BTT and DT patients in the majority of single- and multi-center case series made a separate comparison of BTT and DT outcomes difficult. The resulting descriptive analysis is, therefore, not specific to patients undergoing implantation for either indication but a general overview of outcomes following implantation.

Conclusions

There is an ever-increasing amount of data pertaining to survival and long-term outcomes after LVAD implantation. Studies have consistently shown an increase in survival, quality of life and functional status following cf-LVAD implantation, but these devices remain associated with significant morbidity and mortality in the long-term.

While short-term survival remains comparable with OHT, complications such as bleeding, infection and stroke have been associated with poorer long-term survival, and the cumulative risk of experiencing these adverse events is directly proportional to the duration of support. With more people receiving LVAD support and no commensurate increase in donor organs, these complications are going to be a growing cause of morbidity, mortality and re-hospitalization. While there is a growing understanding of why these complications occur there remains a need for the development of management strategies to effectively minimize these risks. There remains a need for large studies of high quality to examine the long-term outcomes of cf-LVAD for DT indication and for investigating management strategies to minimize the incidence of complications. The findings of this review suggest that despite the increasing occurrence of adverse events over the long-term, patients supported with cf-LVAD continue to experience an improved quality of life and functional status that does not decline with prolonged support. This is testament to the usefulness of cf-LVAD therapy in the treatment of end stage heart failure, an otherwise highly morbid and fatal medical condition.

Acknowledgments

Funding: Principal investigator NM received financial support from the Baird Institute in the form of a scholarship.

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

1. Lippi G, Sanchis-Gomar F. Global epidemiology and future trends of heart failure. *AME Med J* 2020;5:15.
2. Stehlik J, Kobashigawa J, Hunt SA, et al. Honoring 50 Years of Clinical Heart Transplantation in Circulation: In-Depth State-of-the-Art Review. *Circulation* 2018;137:71-87.
3. Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term use of a left ventricular assist device for end-stage heart failure. *N Engl J Med* 2001;345:1435-43.
4. Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. *N Engl J Med* 2009;361:2241-51.
5. Milano CA, Rogers JG, Tatroles AJ, et al. HVAD: The ENDURANCE Supplemental Trial. *JACC Heart Fail* 2018;6:792-802.
6. Schmitto JD, Pya Y, Zimpfer D, et al. Long-term evaluation of a fully magnetically levitated circulatory support device for advanced heart failure-two-year results from the HeartMate 3 CE Mark Study. *Eur J Heart Fail* 2019;21:90-7.
7. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 2009;6:e1000097.
8. Esmore D, Spratt P, Larbalestier R, et al. VentrAssist left ventricular assist device: clinical trial results and Clinical Development Plan update. *Eur J Cardiothorac Surg* 2007;32:735-44.
9. Esmore DS, Kaye D, Salamonsen R, et al. Initial clinical experience with the VentrAssist left ventricular assist device: the pilot trial. *J Heart Lung Transplant* 2008;27:479-85.
10. Morshuis M, Schoenbrodt M, Nojiri C, et al. DuraHeart magnetically levitated centrifugal left ventricular assist system for advanced heart failure patients. *Expert Rev Med Devices* 2010;7:173-83.
11. Bogaev RC, Pamboukian SV, Moore SA, et al. Comparison of outcomes in women versus men using a continuous-flow left ventricular assist device as a bridge to transplantation. *J Heart Lung Transplant* 2011;30:515-22.
12. Strueber M, O'Driscoll G, Jansz P, et al. Multicenter evaluation of an intrapericardial left ventricular assist system. *J Am Coll Cardiol* 2011;57:1375-82.
13. Park SJ, Milano CA, Tatroles AJ, et al. Outcomes in advanced heart failure patients with left ventricular assist devices for destination therapy. *Circ Heart Fail* 2012;5:241-8.
14. Slaughter MS, Pagani FD, McGee EC, et al. HeartWare ventricular assist system for bridge to transplant: combined results of the bridge to transplant and continued access

- protocol trial. *J Heart Lung Transplant* 2013;32:675-83.
15. Najjar SS, Slaughter MS, Pagani FD, et al. An analysis of pump thrombus events in patients in the HeartWare ADVANCE bridge to transplant and continued access protocol trial. *J Heart Lung Transplant* 2014;33:23-34.
 16. Maltais S, Kilic A, Nathan S, et al. PREVENTion of HeartMate II Pump Thrombosis Through Clinical Management: The PREVENT multi-center study. *J Heart Lung Transplant* 2017;36:1-12.
 17. Netuka I, Litzler PY, Berchtold-Herz M, et al. Outcomes in HeartMate II Patients With No Antiplatelet Therapy: 2-Year Results From the European TRACE Study. *Ann Thorac Surg* 2017;103:1262-8.
 18. Rogers JG, Pagani FD, Tatóoles AJ, et al. Intrapericardial Left Ventricular Assist Device for Advanced Heart Failure. *N Engl J Med* 2017;376:451-60.
 19. Gustafsson F, Shaw S, Lavee J, et al. Six-month outcomes after treatment of advanced heart failure with a full magnetically levitated continuous flow left ventricular assist device: report from the ELEVATE registry. *Eur Heart J* 2018;39:3454-60.
 20. Mehra MR, Uriel N, Naka Y, et al. A Fully Magnetically Levitated Left Ventricular Assist Device - Final Report. *N Engl J Med* 2019;380:1618-27.
 21. Strüber M, Sander K, Lahpor J, et al. HeartMate II left ventricular assist device; early European experience. *Eur J Cardiothorac Surg* 2008;34:289-94.
 22. Loforte A, Montalto A, Ranocchi F, et al. Long-term mechanical support with the HeartMate II LVAS. *Transplant Proc* 2009;41:1357-9.
 23. Sandner SE, Zimpfer D, Zrunek P, et al. Age and outcome after continuous-flow left ventricular assist device implantation as bridge to transplantation. *J Heart Lung Transplant* 2009;28:367-72.
 24. Wieselthaler GM, O Driscoll G, Jansz P, et al. Initial clinical experience with a novel left ventricular assist device with a magnetically levitated rotor in a multi-institutional trial. *J Heart Lung Transplant* 2010;29:1218-25.
 25. Drews T, Dandel M, Krabatsch T, et al. Long-term mechanical circulatory support in 198 patients: largest single-center experience worldwide. *ASAIO J* 2011;57:9-16.
 26. Aggarwal A, Pant R, Kumar S, et al. Incidence and management of gastrointestinal bleeding with continuous flow assist devices. *Ann Thorac Surg* 2012;93:1534-40.
 27. Brenyo A, Rao M, Koneru S, et al. Risk of mortality for ventricular arrhythmia in ambulatory LVAD patients. *J Cardiovasc Electrophysiol* 2012;23:515-20.
 28. Menon AK, Götzenich A, Sassmannshausen H, et al. Low stroke rate and few thrombo-embolic events after HeartMate II implantation under mild anticoagulation. *Eur J Cardiothorac Surg* 2012;42:319-23; discussion 323.
 29. Ozbaran M, Yagdi T, Engin C, et al. New circulatory support system: heartware. *Transplant Proc* 2012;44:1726-8.
 30. Raasch H, Jensen BC, Chang PP, et al. Epidemiology, management, and outcomes of sustained ventricular arrhythmias after continuous-flow left ventricular assist device implantation. *Am Heart J* 2012;164:373-8.
 31. Sorensen EN, Pierson RN 3rd, Feller ED, et al. University of Maryland surgical experience with the Jarvik 2000 axial flow ventricular assist device. *Ann Thorac Surg* 2012;93:133-40.
 32. Yuan N, Arnaoutakis GJ, George TJ, et al. The spectrum of complications following left ventricular assist device placement. *J Card Surg* 2012;27:630-8.
 33. Dell'Aquila AM, Schneider SR, Schlarb D, et al. Initial clinical experience with the HeartWare left ventricular assist system: a single-center report. *Ann Thorac Surg* 2013;95:170-7.
 34. Forest SJ, Bello R, Friedmann P, et al. Readmissions after ventricular assist device: etiologies, patterns, and days out of hospital. *Ann Thorac Surg* 2013;95:1276-81.
 35. Kutty RS, Parameshwar J, Lewis C, et al. Use of centrifugal left ventricular assist device as a bridge to candidacy in severe heart failure with secondary pulmonary hypertension. *Eur J Cardiothorac Surg* 2013;43:1237-42.
 36. Lok SI, Martina JR, Hesselink T, et al. Single-centre experience of 85 patients with a continuous-flow left ventricular assist device: clinical practice and outcome after extended support. *Eur J Cardiothorac Surg* 2013;44:e233-8.
 37. Meyer AL, Malehsa D, Bara C, et al. Implantation of rotary blood pumps into 115 patients: a single-centre experience. *Eur J Cardiothorac Surg* 2013;43:1233-6.
 38. Mulloy DP, Bhamidipati CM, Stone ML, et al. Cryoablation during left ventricular assist device implantation reduces postoperative ventricular tachyarrhythmias. *J Thorac Cardiovasc Surg* 2013;145:1207-13.
 39. Saeed D, Arusoglu L, Gazzoli F, et al. Results of the European clinical trial of Arrow CorAide left ventricular assist system. *Artif Organs* 2013;37:121-7.
 40. Sakaguchi T, Matsumiya G, Yoshioka D, et al. DuraHeart™ magnetically levitated left ventricular assist device: Osaka University experience. *Circ J* 2013;77:1736-41.

41. Özalp F, Bhagra S, Bhagra C, et al. Four-year outcomes with third-generation centrifugal left ventricular assist devices in an era of restricted transplantation. *Eur J Cardiothorac Surg* 2014;46:e35-40.
42. Sabashnikov A, Mohite PN, Weymann A, et al. Outcomes after implantation of 139 full-support continuous-flow left ventricular assist devices as a bridge to transplantation. *Eur J Cardiothorac Surg* 2014;46:e59-66.
43. Takeda K, Takayama H, Kalesan B, et al. Long-term outcome of patients on continuous-flow left ventricular assist device support. *J Thorac Cardiovasc Surg* 2014;148:1606-14.
44. Yoshioka D, Matsumiya G, Toda K, et al. Clinical results with Jarvik 2000 axial flow left ventricular assist device: Osaka University Experience. *J Artif Organs* 2014;17:308-14.
45. Ertugay S, Engin C, Nalbantgil S, et al. Postoperative Outcomes of the Largest HeartMate-II Experience in Turkey. *Transplant Proc* 2015;47:1499-502.
46. Hata H, Fujita T, Shimahara Y, et al. Early and mid-term outcomes of left ventricular assist device implantation and future prospects. *Gen Thorac Cardiovasc Surg* 2015;63:557-64.
47. Iacovoni A, Centofanti P, Attisani M, et al. Low incidence of gastrointestinal bleeding and pump thrombosis in patients receiving the INCOR LVAD system in the long-term follow-up. *Int J Artif Organs* 2015;38:542-7.
48. Kimura M, Kinoshita O, Nawata K, et al. Midterm outcome of implantable left ventricular assist devices as a bridge to transplantation: Single-center experience in Japan. *J Cardiol* 2015;65:383-9.
49. Lushaj EB, Badami A, Osaki S, et al. Impact of age on outcomes following continuous-flow left ventricular assist device implantation. *Interact Cardiovasc Thorac Surg* 2015;20:743-8.
50. Ammirati E, Oliva FG, Colombo T, et al. Mid-term survival after continuous-flow left ventricular assist device versus heart transplantation. *Heart Vessels* 2016;31:722-33.
51. Daneshmand MA, Krishnamoorthy A, Samsky MD, et al. Comparison of 2-Year Outcomes of Extended Criteria Cardiac Transplantation Versus Destination Left Ventricular Assist Device Therapy Using Continuous Flow. *Am J Cardiol* 2015;116:573-9.
52. John R, Holley CT, Eckman P, et al. A Decade of Experience With Continuous-Flow Left Ventricular Assist Devices. *Semin Thorac Cardiovasc Surg* 2016;28:363-75.
53. Raichlin E, Baibhav B, Lowes BD, et al. Outcomes in Patients with Severe Preexisting Renal Dysfunction After Continuous-Flow Left Ventricular Assist Device Implantation. *ASAIO J* 2016;62:261-7.
54. Sileshi B, O'Hara BK, Davis ME, et al. Outcomes of Patients Implanted Using a Left Thoracotomy Technique for a Miniaturized Centrifugal Continuous-Flow Pump. *ASAIO J* 2016;62:539-44.
55. Xuereb L, Go PH, Kaur B, et al. Impact of Preoperative Atrial Fibrillation on Postoperative Thromboembolic Events After Left Ventricular Assist Device Implantation. *Ann Thorac Surg* 2016;102:1543-9.
56. Centofanti P, Baronetto A, Attisani M, et al. Thrombosis in left ventricular assistance device with centrifugal technology: is early thrombolysis a better solution? *Int J Artif Organs* 2017;40:629-35.
57. Hanke JS, Rojas SV, Cvitkovic T, et al. First results of HeartWare left ventricular assist device implantation with tunnelling of the outflow graft through the transverse sinus. *Interact Cardiovasc Thorac Surg* 2017;25:503-8.
58. Steffen RJ, Blackstone EH, Smedira NG, et al. Optimal Timing of Heart Transplant After HeartMate II Left Ventricular Assist Device Implantation. *Ann Thorac Surg* 2017;104:1569-76.
59. Tozzi P, Banfi C, Ahmadov K, et al. HeartMate 3 in Lowest INTERMACS Profile Cohort: The Swiss Experience. *ASAIO J* 2017;63:752-8.
60. Carrozzini M, Bejko J, Gambino A, et al. Results of new-generation intrapericardial continuous flow left ventricular assist devices as a bridge-to-transplant. *J Cardiovasc Med (Hagerstown)* 2018;19:739-47.
61. Tahsili-Fahadan P, Curfman DR, Davis AA, et al. Cerebrovascular Events After Continuous-Flow Left Ventricular Assist Devices. *Neurocrit Care* 2018;29:225-32.
62. Volkovicher N, Kurihara C, Critsinelis A, et al. Outcomes in patients with advanced heart failure and small body size undergoing continuous-flow left ventricular assist device implantation. *J Artif Organs* 2018;21:31-8.
63. Yin MY, Ruckel S, Kfoury AG, et al. Novel Model to Predict Gastrointestinal Bleeding During Left Ventricular Assist Device Support. *Circ Heart Fail* 2018;11:e005267.
64. Braun OÖ, Nilsson J, Gustafsson F, et al. Continuous-flow LVADs in the Nordic countries: complications and mortality and its predictors. *Scand Cardiovasc J* 2019;53:14-20.
65. Jorde UP, Shah AM, Sims DB, et al. Continuous-Flow Left Ventricular Assist Device Survival Improves With Multidisciplinary Approach. *Ann Thorac Surg* 2019;108:508-16.
66. Kyvernitis A, Pappas O, Farmakiotis D, et al.

- Bloodstream Infections in Continuous Flow Left Ventricular Assist Device Recipients: Diagnostic and Clinical Implications. *ASAIO J* 2019;65:798-805.
67. John R, Naka Y, Smedira NG, et al. Continuous flow left ventricular assist device outcomes in commercial use compared with the prior clinical trial. *Ann Thorac Surg* 2011;92:1406-13; discussion 1413.
 68. Goldstein DJ, Meyns B, Xie R, et al. Third Annual Report from the ISHLT Mechanically Assisted Circulatory Support Registry: A comparison of centrifugal and axial continuous-flow left ventricular assist devices. *J Heart Lung Transplant* 2019;38:352-63.
 69. Kormos RL, Cowger J, Pagani FD, et al. The Society of Thoracic Surgeons Intermacs database annual report: Evolving indications, outcomes, and scientific partnerships. *J Heart Lung Transplant* 2019;38:114-26.
 70. Wever-Pinzon O, Selzman CH, Drakos SG, et al. Pulsatility and the risk of nonsurgical bleeding in patients supported with the continuous-flow left ventricular assist device HeartMate II. *Circ Heart Fail* 2013;6:517-26.
 71. Uriel N, Pak SW, Jorde UP, et al. Acquired von Willebrand syndrome after continuous-flow mechanical device support contributes to a high prevalence of bleeding during long-term support and at the time of transplantation. *J Am Coll Cardiol* 2010;56:1207-13.
 72. Kirklin JK, Naftel DC, Kormos RL, et al. Fifth INTERMACS annual report: risk factor analysis from more than 6,000 mechanical circulatory support patients. *J Heart Lung Transplant* 2013;32:141-56.
 73. Mudd JO, Cuda JD, Halushka M, et al. Fusion of aortic valve commissures in patients supported by a continuous axial flow left ventricular assist device. *J Heart Lung Transplant* 2008;27:1269-74.
 74. Baumwol J, Macdonald PS, Keogh AM, et al. Right heart failure and "failure to thrive" after left ventricular assist device: clinical predictors and outcomes. *J Heart Lung Transplant* 2011;30:888-95.
 75. Green CP, Porter CB, Bresnahan DR, et al. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. *J Am Coll Cardiol* 2000;35:1245-55.
 76. Rector TS, Cohn JN. Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. *Am Heart J* 1992;124:1017-25.
 77. Stulak JM, Davis ME, Haglund N, et al. Adverse events in contemporary continuous-flow left ventricular assist devices: A multi-institutional comparison shows significant differences. *J Thorac Cardiovasc Surg* 2016;151:177-89.
 78. McIlvennan CK, Magid KH, Ambardekar AV, et al. Clinical outcomes after continuous-flow left ventricular assist device: a systematic review. *Circ Heart Fail* 2014;7:1003-13.
 79. Yoshioka D, Sawa Y. Clinical results of continuous-flow left ventricular assist device(LVAD) for severe heart failure patients. *Kyobu Geka* 2013;66:57-61.
 80. Miller LW, Pagani FD, Russell SD, et al. Use of a continuous-flow device in patients awaiting heart transplantation. *N Engl J Med* 2007;357:885-96.
 81. Zierer A, Melby SJ, Voeller RK, et al. Late-onset driveline infections: the Achilles' heel of prolonged left ventricular assist device support. *Ann Thorac Surg* 2007;84:515-20.
 82. Schulman AR, Martens TP, Christos PJ, et al. Comparisons of infection complications between continuous flow and pulsatile flow left ventricular assist devices. *J Thorac Cardiovasc Surg* 2007;133:841-2.
 83. John R, Kamdar F, Eckman P, et al. Lessons learned from experience with over 100 consecutive HeartMate II left ventricular assist devices. *Ann Thorac Surg* 2011;92:1593-9; discussion 1599-600.
 84. Stern DR, Kazam J, Edwards P, et al. Increased incidence of gastrointestinal bleeding following implantation of the HeartMate II LVAD. *J Card Surg* 2010;25:352-6.
 85. Slaughter MS, Pagani FD, Rogers JG, et al. Clinical management of continuous-flow left ventricular assist devices in advanced heart failure. *J Heart Lung Transplant* 2010;29:S1-39.
 86. Morgan JA, Paone G, Nemeh HW, et al. Gastrointestinal bleeding with the HeartMate II left ventricular assist device. *J Heart Lung Transplant* 2012;31:715-8.
 87. Crow S, John R, Boyle A, et al. Gastrointestinal bleeding rates in recipients of nonpulsatile and pulsatile left ventricular assist devices. *J Thorac Cardiovasc Surg* 2009;137:208-15.
 88. Cannegieter SC, Rosendaal FR, Briët E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. *Circulation* 1994;89:635-41.
 89. Hayes HM, Dembo LG, Larbalestier R, et al. Management options to treat gastrointestinal bleeding in patients supported on rotary left ventricular assist devices: a single-center experience. *Artif Organs* 2010;34:703-6.
 90. Crow S, Chen D, Milano C, et al. Acquired von Willebrand syndrome in continuous-flow ventricular assist device recipients. *Ann Thorac Surg* 2010;90:1263-9; discussion 1269.

91. Geisen U, Heilmann C, Beyersdorf F, et al. Non-surgical bleeding in patients with ventricular assist devices could be explained by acquired von Willebrand disease. *Eur J Cardiothorac Surg* 2008;33:679-84.
92. Crow S, Milano C, Joyce L, et al. Comparative analysis of von Willebrand factor profiles in pulsatile and continuous left ventricular assist device recipients. *ASAIO J* 2010;56:441-5.
93. Tsai HM, Sussman II, Nagel RL. Shear stress enhances the proteolysis of von Willebrand factor in normal plasma. *Blood* 1994;83:2171-9.
94. Siedlecki CA, Lestini BJ, Kottke-Marchant KK, et al. Shear-dependent changes in the three-dimensional structure of human von Willebrand factor. *Blood* 1996;88:2939-50.
95. Klovaitte J, Gustafsson F, Mortensen SA, et al. Severely impaired von Willebrand factor-dependent platelet aggregation in patients with a continuous-flow left ventricular assist device (HeartMate II). *J Am Coll Cardiol* 2009;53:2162-7.
96. John R, Lee S. The biological basis of thrombosis and bleeding in patients with ventricular assist devices. *J Cardiovasc Transl Res* 2009;2:63-70.
97. Letsou GV, Shah N, Gregoric ID, et al. Gastrointestinal bleeding from arteriovenous malformations in patients supported by the Jarvik 2000 axial-flow left ventricular assist device. *J Heart Lung Transplant* 2005;24:105-9.
98. Demirozu ZT, Radovancevic R, Hochman LF, et al. Arteriovenous malformation and gastrointestinal bleeding in patients with the HeartMate II left ventricular assist device. *J Heart Lung Transplant* 2011;30:849-53.
99. Teuteberg JJ, Cleveland JC Jr, Cowger J, et al. The Society of Thoracic Surgeons Intermacs 2019 Annual Report: The Changing Landscape of Devices and Indications. *Ann Thorac Surg* 2020;109:649-60.
100. Topkara VK, Kondareddy S, Malik F, et al. Infectious complications in patients with left ventricular assist device: etiology and outcomes in the continuous-flow era. *Ann Thorac Surg* 2010;90:1270-7.

Cite this article as: McNamara N, Narroway H, Williams M, Brookes J, Farag J, Cistulli D, Bannon P, Marasco S, Potapov E, Loforte A. Contemporary outcomes of continuous-flow left ventricular assist devices—a systematic review. *Ann Cardiothorac Surg* 2021;10(2):186-208. doi: 10.21037/acs-2021-cfmcs-35